Apogee Therapeutics (APGE) Competitors $37.40 +0.13 (+0.34%) As of 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock APGE vs. LEGN, ABVX, AXSM, RNA, NUVL, MRUS, CRSP, TGTX, ACAD, and KRYSShould you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Legend Biotech (LEGN), Abivax (ABVX), Axsome Therapeutics (AXSM), Avidity Biosciences (RNA), Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Apogee Therapeutics vs. Its Competitors Legend Biotech Abivax Axsome Therapeutics Avidity Biosciences Nuvalent Merus CRISPR Therapeutics TG Therapeutics ACADIA Pharmaceuticals Krystal Biotech Apogee Therapeutics (NASDAQ:APGE) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk. Do analysts prefer APGE or LEGN? Apogee Therapeutics currently has a consensus target price of $97.29, indicating a potential upside of 160.16%. Legend Biotech has a consensus target price of $74.22, indicating a potential upside of 123.47%. Given Apogee Therapeutics' higher probable upside, research analysts clearly believe Apogee Therapeutics is more favorable than Legend Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Which has more volatility and risk, APGE or LEGN? Apogee Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Do insiders & institutionals believe in APGE or LEGN? 79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 42.8% of Apogee Therapeutics shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, APGE or LEGN? Legend Biotech has higher revenue and earnings than Apogee Therapeutics. Legend Biotech is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApogee TherapeuticsN/AN/A-$182.15M-$4.13-9.05Legend Biotech$627.24M9.77-$177.03M-$0.88-37.74 Is APGE or LEGN more profitable? Apogee Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -40.83%. Legend Biotech's return on equity of -32.00% beat Apogee Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Apogee TherapeuticsN/A -34.65% -32.76% Legend Biotech -40.83%-32.00%-20.07% Does the media refer more to APGE or LEGN? In the previous week, Apogee Therapeutics had 4 more articles in the media than Legend Biotech. MarketBeat recorded 12 mentions for Apogee Therapeutics and 8 mentions for Legend Biotech. Apogee Therapeutics' average media sentiment score of 1.21 beat Legend Biotech's score of 1.21 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryApogee Therapeutics beats Legend Biotech on 8 of the 15 factors compared between the two stocks. Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APGE vs. The Competition Export to ExcelMetricApogee TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.72B$3.15B$5.82B$10.17BDividend YieldN/A2.32%5.69%4.60%P/E Ratio-9.0421.4374.6725.98Price / SalesN/A256.94454.5485.61Price / CashN/A45.3337.0859.91Price / Book2.359.6512.186.31Net Income-$182.15M-$53.29M$3.29B$270.86M7 Day Performance-1.25%0.44%1.08%3.46%1 Month Performance1.89%9.06%7.32%6.57%1 Year Performance-23.98%13.13%63.11%28.39% Apogee Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APGEApogee Therapeutics2.9176 of 5 stars$37.40+0.3%$97.29+160.2%-26.4%$1.72BN/A-9.0491News CoveragePositive NewsLEGNLegend Biotech3.2748 of 5 stars$34.73+1.0%$74.22+113.7%-32.0%$6.41B$627.24M-39.472,609Positive NewsABVXAbivax2.5871 of 5 stars$81.03-0.7%$92.33+13.9%+631.6%$6.12BN/A0.0061News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap DownAXSMAxsome Therapeutics4.9108 of 5 stars$121.28-0.4%$178.00+46.8%+35.1%$6.05B$385.69M-23.92380Positive NewsInsider TradeRNAAvidity Biosciences2.1142 of 5 stars$46.58-4.1%$67.00+43.8%+1.2%$5.99B$10.90M-13.08190Trending NewsAnalyst ForecastInsider TradeGap UpNUVLNuvalent3.0142 of 5 stars$76.58+0.7%$120.80+57.7%-4.0%$5.52BN/A-15.6340Positive NewsMRUSMerus3.0683 of 5 stars$65.84-0.4%$88.75+34.8%+38.8%$4.98B$36.13M-11.9737Positive NewsCRSPCRISPR Therapeutics3.3026 of 5 stars$51.83-2.3%$71.60+38.1%+23.0%$4.71B$37.31M-9.55460Positive NewsTGTXTG Therapeutics4.149 of 5 stars$29.33+1.3%$46.25+57.7%+40.7%$4.65B$329M79.27290Positive NewsACADACADIA Pharmaceuticals4.3958 of 5 stars$25.99-0.9%$28.88+11.1%+51.7%$4.38B$957.80M19.54510Positive NewsAnalyst ForecastKRYSKrystal Biotech4.9344 of 5 stars$147.70-2.0%$210.38+42.4%-27.4%$4.27B$290.52M30.02210Positive News Related Companies and Tools Related Companies LEGN Competitors ABVX Competitors AXSM Competitors RNA Competitors NUVL Competitors MRUS Competitors CRSP Competitors TGTX Competitors ACAD Competitors KRYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APGE) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredElon’s new AI play could hand regular Americans a Tesla‑like paydayElon Musk just launched his boldest AI project yet... And if history is any guide — it could make early inv...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APGE Stock Alerts